Acute Coronary Syndrome
Conditions
Brief summary
A Single-center prospective pilot study enrolling chest pain patients. CD 26 measurement will be performed and compared to troponin µs for early triage of these patients. This novel biomarker of myocardial ischemia (CD26) will be measured at the time of first medical contact (T0) and after 30 min simultaneously o troponin Ic. All patients aged over 18 years with chest pain which may be related to acute coronary syndrome requiring pre hospital medical contact through the Emergency Medical Service.
Detailed description
First objectives: demonstrating the early positivity of CD26 compared to ultra-sensitive troponin.
Interventions
OTHERblood samples
Sponsors
Assistance Publique Hopitaux De Marseille
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject with compatible symptoms with an acute coronary syndrome, for at least 15 minutes and not older than 3 hours (eg discomfort, tightness or chest pain, pain radiating to the left arm or two arms, pain in the jaw, pain in the back / neck / stomach, breathlessness , cold sweats, nausea / vomiting , dizziness ) * Man or woman, * Patient Did not receive heparin or low molecular weight heparin (LMWH ) before the initial blood sample , * Patient Agreeing to participate in the study and who signed an informed consent
Exclusion criteria
* Minor or major patient trust * Patient Not having signed informed consent (refusal , physical or mental disability ... ) * Patient Who received anticoagulation before carrying blood samples * Patient With a progressive septic processes , neoplasia undergoing treatment, dialyzed kidney failure, a history of surgery or coronary angioplasty less than six months. * Transplanted heart, renal or hepatic * heart attack * Subject Whose symptoms clearly eliminates acute coronary syndrome ( penetrating trauma, traumatic injury by crushing ... ) * Patient Died between the time of inclusion and arrival in the cardiology intensive care ( SIC ) * Patient Withdrawing consent under study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| blood sample: dosage of the copeptin | 12 months | — |
| blood sample: dosage of troponin | 12 months | — |
| blood sample : dosage of IMA | 12 months | IMA (Albumin modified by the ischaemia) |
| blood sample: dosage of adenosin | 12months | — |
| blood sample : dosage of CD26 | 12 MONTHS | demonstrating the early positivity of CD26 compared to ultra-sensitive troponin. |
Countries
France
Outcome results
None listed